恩扎卢胺对比比卡鲁胺治疗非转移性去势抵抗性前列腺癌:STRIVE 试验预设亚组分析
STRIVE 为 2 期随机双盲试验,本预设亚组分析纳入 139 例非转移性去势抵抗性前列腺癌(nmCRPC)患者,随机接受恩扎卢胺 160 mg/日联合 ADT(n=70)或比卡鲁胺 50 mg/日联合 ADT(n=69)。中位随访 17 个月,恩扎卢胺较比卡鲁胺降低进展或死亡风险 76%(HR 0.24,95%CI 0.14-0.42),降低 PSA 进展风险 82%(HR 0.18,95%CI 0.10-0.34)。
要点
- nmCRPC 患者中恩扎卢胺较比卡鲁胺显著降低进展或死亡风险(HR 0.24)。
- 恩扎卢胺较比卡鲁胺显著降低 PSA 进展风险(HR 0.18)。
- 最常见不良事件为疲乏(36.2%)、潮热(20.3%)等。
核心结论
- 在 nmCRPC 患者中,恩扎卢胺对比比卡鲁胺可降低进展或死亡风险及 PSA 进展风险。
研究设计与样本
- STRIVE 为 2 期随机双盲试验,本分析为预设亚组分析,纳入 139 例 nmCRPC 患者,按疾病分期分层随机分组。
- 恩扎卢胺组 70 例接受恩扎卢胺 160 mg/日联合 ADT,比卡鲁胺组 69 例接受比卡鲁胺 50 mg/日联合 ADT。
主要发现
- 中位随访 17 个月,恩扎卢胺较比卡鲁胺降低 nmCRPC 患者进展或死亡风险 76%(HR 0.24,95%CI 0.14-0.42)。
- 恩扎卢胺较比卡鲁胺降低 nmCRPC 患者 PSA 进展风险 82%(HR 0.18,95%CI 0.10-0.34)。
- 恩扎卢胺组最常见不良事件为疲乏(36.2%)、潮热(20.3%)、食欲下降(17.4%)、头晕(17.4%)和恶心(17.4%)。
临床怎么用
- 对 nmCRPC 患者,恩扎卢胺联合 ADT 可作为较比卡鲁胺联合 ADT 更有效降低进展风险的选项。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In the phase 2, randomized, double-blind STRIVE trial, enzalutamide significantly reduced the risk of prostate cancer progression or death versus bicalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) and nonmetastatic CRPC (nmCRPC). The objective of this protocol-specified subgroup analysis of STRIVE was to investigate the benefit of enzalutamide versus bicalutamide specifically in patients with nmCRPC. METHODS: Patients (N = 139) were stratified by disease stage and randomized to enzalutamide 160 mg/day plus androgen deprivation therapy (ADT; n = 70) or bicalutamide 50 mg/day plus ADT (n = 69). RESULTS: Baseline characteristics of patients with nmCRPC were comparable between groups. At a median of 17 months follow-up, enzalutamide reduced the risk of progression or death by 76% versus bicalutamide in patients with nmCRPC (hazard ratio [HR], 0.24; 95% CI 0.14-0.42). Enzalutamide reduced risk of prostate-specific antigen progression by 82% versus bicalutamide in patients with nmCRPC (HR, 0.18; 95% CI 0.10-0.34). The most frequently reported adverse events by patients receiving enzalutamide were fatigue (36.2%), hot flush (20.3%), decreased appetite (17.4%), dizziness (17.4%), and nausea (17.4%). CONCLUSIONS: This STRIVE subgroup analysis of patients with nmCRPC illustrates the benefit of enzalutamide in reducing the risk of progression or death versus bicalutamide in patients with nmCRPC. TRIAL REGISTRATION: ClinicalTrials.gov identifier NCT01664923.
引用
- Penson DF, Armstrong AJ, Concepcion RS, et al. Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial. Prostate Cancer Prostatic Dis. 2021. PMID: 34621011. doi:10.1038/s41391-021-00465-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。